ObsEva Past Earnings Performance

Past criteria checks 0/6

ObsEva has been growing earnings at an average annual rate of 7.1%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 86.9% per year.

Key information

7.0%

Earnings growth rate

23.0%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate86.9%
Return on equity-352.2%
Net Margin-152.2%
Next Earnings Update14 Aug 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ObsEva makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:OBSN N Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2220-30250
30 Sep 224-772525
30 Jun 220-642836
31 Mar 220-502543
31 Dec 2122-53250
30 Sep 210-571856
30 Jun 210-821465
31 Mar 210-811366
31 Dec 200-831268
30 Sep 200-851270
30 Jun 200-881472
31 Mar 200-1051885
31 Dec 190-1091988
30 Sep 190-1082086
30 Jun 190-991980
31 Mar 190-831667
31 Dec 180-771463
30 Sep 180-741361
30 Jun 180-721359
31 Mar 180-711358
31 Dec 170-671355
30 Sep 170-611349
30 Jun 170-521241
31 Mar 170-41933
31 Dec 160-30624
30 Sep 160-26520
30 Jun 160-21318
31 Mar 160-20316
31 Dec 150-20317
31 Dec 140-13211

Quality Earnings: OBSN N is currently unprofitable.

Growing Profit Margin: OBSN N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OBSN N is unprofitable, but has reduced losses over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare OBSN N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBSN N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).


Return on Equity

High ROE: OBSN N has a negative Return on Equity (-352.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/18 12:41
End of Day Share Price 2023/04/20 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ObsEva SA is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Mayur SomaiyaBMO Capital Markets Equity Research
Edward NashCanaccord Genuity